#news #biotech Arena’s pain drug fails phase 2b, prompting review of ‘strategic options’

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Arena’s pain drug fails phase 2b, prompting review of ‘strategic options’ .Arena’s pain drug fails phase 2b, prompting review of ‘strategic options’
ntaylor
Wed, 03/03/2021 – 05:13

from FierceBiotech: Biotech https://ift.tt/3kDu4Ay